β β β Interventions (
π
) Samples and Characteristics Hoehn and Yahr β β β Included trials Eligibility criteria1 Study Designs Drug/dosage Male/female (
π
); age (years); duration (years)
Staging scale (stage)β:βcase (
π
) Course of treatment Outcomes Intergroup differences β β β Trial Control Trial Control Trial Control β β β
Cui et al. [17 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (stratified randomized) and controlled nonblind parallel study BuShenPing ChanFang 1βdose/d# Madopar 62.5β500βmg/per time (pt), bid-qid M31/F21 Mean age: 67.9 Β± 16.5 Disease duration: 2β12 M25/F10 Mean age: 65.5 Β± 16.5 Duration: 1β10 1.5β3β:β22 4β:β13 1.5~3β:β25 4β:β10 3βmon (1) UPDRS (2) Clinical symptom (3) Adverse effect* (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
or
π
<
0
.
0
1
Wang et al. [18 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (simple randomized) and controlled parallel study ZiYinXiFeng HuoXueTang 1βdose/d# Madopar 125βmg/pt for 1 week; then 250βmg/ pt bid M11/F9 Age range: 45β74 Disease duration: 7βmoβ6βy M10/F10 Age range: 42β75 Disease duration: 6βmoβ5βy nr nr 3βmon (1) UPDRS (2) Tremble function (1)
π
<
0
.
0
1
(2)
π
<
0
.
0
1
Wang et al. [19 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled nonblind parallel study CHM according to syndrome differentiation# Madopar <3 piece/d; If stiff, add amantadine 0.1-0.2/d M33/F20 Mean age: 63.91 Β± 9.3 Disease duration: nr M30/F20 Mean age: 62.62 Β± 9.54 Disease duration: nr nr nr 90βd (1) UPDRS II, III (2) Clinical symptom (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
Shen and Yuan [20 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled parallel study ZiBuGanShen 1βdose/d# Madopar, Sinemet, Artane; no detailed information concern on the dosage M26/F14 Mean age: 71.30 Β± 6.92 Disease duration: 4.30 Β± 2.31 M20/F10 Age range: 67.91 Β± 7.64 Disease duration: 3.91 Β± 2.01 2β:β8 2.5β:β18 3β:β10 4β:β4 2β:β6 2.5β:β15 3β:β6 4β:β5 3βmon (1) UPDRS II, III (2) Webster scale (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
Luo et al. [21 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (simple randomized) and controlled nonblind parallel study PaBing I Hao 1βdose/d# Madopar; no detailed information concern on the dosage M18/F4 Mean age: 64.54 Β± 10.61 Disease duration: 5.19 Β± 5.22 M12/F7 Mean age: 66.80 Β± 9.15 Disease duration: 5.57 Β± 3.56 1β:β6 2β:β10 3β:β3 4β:β3 1β:β4 2β:β10 3β:β3 4β:β2 3βmon (1) UPDRS (1)
π
<
0
.
0
5
Zheng and Luo [22 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (simple randomized) and controlled nonblind parallel study PaBing III Hao 1βdose/d# Madopar 125βmg/pt, bid for 1 w; then 250βmg/pt, bid M15/F15 Mean age: 63.43 Β± 10.09βy Disease duration: 6βmoβ15βy M19/F11 Mean age: 62.30 Β± 6.82βy Disease duration: 9βmoβ13βy 1β:β12 2β:β11 3β:β7 1β:β6 2β:β15 3β:β9 3βmon (1) UPDRS (2) Hoehn-yahr class (1)
π
<
0
.
0
5
(2)
π
>
0
.
0
5
Xie et al. [23 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled nonblind parallel study JunFuKangJiao Nang 1.5βg/per time (pt), tid # Madopar 125βmg/pt, tid M: 8/F: 6 Mean age: 59.00 Β± 9.64βy Disease duration: nr M: 7/F: 7 Mean age: 58.6 Β± 12.0βy Disease duration: nr nr nr 6βmon (1) UPDRS (2) Adverse effect (3) Clinical symptom (1)
π
<
0
.
0
1
(2) nr (3)
π
<
0
.
0
5
Cheng et al. [24 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled nonblind parallel study XiFengDingChan Wan 6βg/pt, tid # Madopar for 12 w; convention dosage add the dosage when effect decline dosage subtract 62.5 mg/d over the 2 weeks M12/F8 Mean age: 63 Β± 6.07 Disease duration: nr M11/F9 Mean age: 60.35 Β± 6.73 Disease duration: nr nr nr 12βw (1) UPDRS (2) Madopar dosage (1)
π
<
0
.
0
1
(2)
π
<
0
.
0
1
Zhu et al. [25 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled nonblind parallel study DingZhenTang 1βdose/d# Antiparkinsonian drug, no detailed information M23/F11 Mean age: 72.2 Β± 6.7 Disease duration: 3.3 Β± 2.4 M21/F10 Mean age: 70.0 Β± 7.6 Disease duration: 3.5 Β± 2.5 1β:β4 1.5β:β4 2β:β7 2.5β:β10 3β:β8 1β:β4 1.5β:β3 2β:β6 2.5β:β9 3β:β9 6βmo (1) UPDRS (2) Autonomic nerve function (1)
π
=
0
.
0
0
1
8
(2)
π
>
0
.
0
5
(constipation
π
<
0
.
0
1
)
Zhao et al. [26 ] CN, ADJ Multicenter CNDS for PD in 1984 Randomized (case randomized) and controlled blind parallel study GuiLingPaAnJiao Nang 3 pill/pt tid# Placebo 3 pill/pt tid; Madopar, Sinemet plus Placebo 3 pill/pt tid M46/F29 Mean age: 64.86 Β± 9.85 Disease duration: 4.27 Β± 3.44 M47/F32 Mean age: 65.63 Β± 8.51 Disease duration: 4.59 Β± 3.82 nr nr 12βw (1) UPDRS II, III, total (2) Levodopa dosage (3) Clinical effect (1)
π
<
0
.
0
5
or
π
<
0
.
0
1
(2)
π
<
0
.
0
5
(3)
π
>
0
.
0
5
Kum et al. [27 ] HK, ADJ monocenter UK Brain Bank standard Randomized (computer- generated randomized) and controlled double-blind parallel study JiaWeiLiuJunZi Tang; no detailed information concern on the dosage# Placebo with each dose of their levodopa treatment M14/F8 Mean age: 64.82 Β± 8.88βy Disease duration: 5.44 Β± 5.26 M17/F8 Mean age: 60.88 Β± 9.41 Disease duration: 5.36 Β± 5.27 nr nr 24βw (1) PDQ-39 (2) UPDRS (3) GDS (4) SF-36 (5) DSQS (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
(3)
π
>
0
.
0
5
(4)
π
>
0
.
0
5
(5)
π
>
0
.
0
5
Yang et al. [28 ] CN, ADJ Multicenter UK Brain Bank standard Randomized (central random System randomized) and controlled blind parallel study BuShenHuoXue Particle 1βdose/d# Madopar 375β1000βmg/pt tid-qid; placebo 1βdose/d M29/F26 Mean age: 66.4 Β± 9.1 Disease duration: 5.3 Β± 3.1 M35/F16 Mean age: 67.5 Β± 9.5 Disease duration: 5.0 Β± 3.9 nr nr 3βmon (1) UPDRS III (2) Movement experiment (3) 10βm reentry run (4) Muscular tension (1)
π
<
0
.
0
5
(2)
π
>
0
.
0
5
(3)
π
<
0
.
0
5
(4)
π
<
0
.
0
5
Yuan et al. [29 ] CN, ADJ Multicenter CNDS for PD in 1984 Randomized (block randomization) and controlled blind parallel study ShuDiPingChan Tang 2 bag/ptbid; XieWuJiaoNang 8βpill/pt, bid# Antiparkinsonian drug; no definite information M18/F12 Mean age: 69.5 Β± 7.81 Disease duration: 7.43 Β± 1.64 M16/F14 Mean age: 68.6 Β± 7.32 Disease duration: 7.35 Β± 1.82 2β:β10 2.5β:β28 3β:β12 4β:β10 2β:β12 2.5β:β30 3β:β8 4β:β10 3βmon (1) UPDRS (2) Clinical symptom (3) H-Y Stage (4) On-off phenomenon (5) Levodopa dosage (1)
π
<
0
.
0
1
(2)
π
<
0
.
0
1
(3)
π
<
0
.
0
5
(4)
π
<
0
.
0
1
(5)
π
>
0
.
0
5
Hong [30 ] CN, ADJ monocenter CNDS for PD in 2006 Randomized (method unreported) and controlled nonblind parallel study CHM, No detailed information# Madopar 62.5β125βmg/pt, bid-tid; Adjust the dosage according to the effect M23/F15 Mean age: 72.2 Β± 6.6 Disease duration: 19.6 Β± 5.4 M21/, F17 Mean age: 73.1 Β± 6.9 Disease duration: 20.5 Β± 5.8 nr nr 6βmon (1) UPDRS III (2) UPDRS IV (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
Fan et al. 2010 [31 ] CN, ADJ monocenter CNDS for PD in 2006 Randomized simple randomized) and controlled nonblind parallel study PaBing II Hao 1dose/d continue 3 w; interval 1 w for 3 mon# Madopar 125βmg/pt, bid for 1 w; Then 250,125,125βmg/pt (morning, middle, night, resp.) for 3 mon 30 PD Mean age: nr Disease duration: nr 30 PD Mean age: nr Disease duration: nr nr nr 3βmon (1) UPDRS (2) Clinical symptom (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
Dou and Diao [32 ] CN, ADJ monocenter CNDS for PD in 1984 Randomized (method unreported) and controlled nonblind parallel study BuShenHuoXue Tang 600βmL/d# Madopar 125βmg/pt, tid M22/F13 Mean age: 54.7 Β± 11.5 Disease duration: 3.7 Β± 1.9 M21/F14 Mean age: 53.5 Β± 11.9 Disease duration: 3.4 Β± 1.8 nr nr 3βmon (1) UPDRS (2) Clinical symptom (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
Li et al. [33 ] CN, ADJ monocenter UK Brain Bank standard Randomized (method unreported) and controlled nonblind parallel study BuShenHuoXueYin 1βdose/d divide twice 150βmL/pt# Madopar 125βmgβ1500βmg/d; Sinemet 125βmgβ500βmg/d; Benzhexol 2β6βmg/d; Amantadine100β300βmg/d; Trastal 50β150βmg/d; M30/F17 Mean age: 65.2 Β± 7.8βy Disease duration: 5.61 Β± 4.18 M25/F19 Mean age: 65.3 Β± 8.8βy Disease duration: 5.97 Β± 4.24 1.5β:β4 2β:β16 2.5β:β14 3β:β10 4β:β3 1.5β:β3 2β:β16 2.5β:β15 3β:β8 4β:β2 3βmon (1) UPDRS total (2) UPDRS II (3) UPDRS III (4) Clinical effect (5) H-Y stage (6) Motor complications (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
(3)
π
>
0
.
0
5
(4)
π
<
0
.
0
5
(5)
π
>
0
.
0
5
(6) Reduced
Wu et al. [34 ] CN, ADJ monocenter CNDS for PD in 2006 Randomized (random- number table) and controlled nonblind parallel study ZhichanpingPaTang 1βdose/d, divide twice 600βmL/d# Madopar 125βmg/pt, bid for 1βw; then 250, 125, 125βmg/pt (morning, middle, night, resp.) M20/F20 Mean age: 69.28 Β± 10.21 Disease duration: 3.94 Β± 3.02 M22/F18 Mean age: 68.8 Β± 7.59 Disease duration: 4.44 Β± 3.17 1β2.5β:β29 3β:β11 4-5β:β0 1β2.5β:β28 3β:β12 4-5β:β0 3βmon (1) UPDRS I (2) UPDRS II (3) UPDRS III (4) UPDRS IV (5) LSIB scale (6) PDQ (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
(3)
π
<
0
.
0
5
(4)
π
<
0
.
0
5
(5)
π
<
0
.
0
5
(6)
π
<
0
.
0
5
Pan et al. [35 ] CN, ADJ monocenter UK Brain Bank Standard Randomized (random numbers) and controlled blind parallel study Zengxiao Anshen Zhichan 8βg/d# Placebo granule; antiparkinsonian drug M34/F22 Mean age: 62.82 Β± 10.31 Disease duration: 5.73 Β± 4.81 M21/F14 Mean age: 63.1 Β± 10.2 Disease duration: 5.81 Β± 3.24 nr nr 13βw (1) AMI counts (2) UPDRS II, III, IV (3) Power-law Exponent Ξ± (4) Secondary symptom score (1)
π
<
0
.
0
5
(2)
π
<
0
.
0
5
(3)
π
<
0
.
0
1
(4)
π
<
0
.
0
5
or
π
<
0
.
0
1